Ahmed Fouad Kotb1, Shelley Spaner2, Trafford Crump1, Matthew Eric Hyndman3. 1. Department of Urology, Southern Alberta Institute of Urology, 7007 14 St SW, Calgary, AB, T2V 1P9, Canada. 2. Department of Radiology, Southern Alberta Institute of Urology, Calgary, AB, Canada. 3. Department of Urology, Southern Alberta Institute of Urology, 7007 14 St SW, Calgary, AB, T2V 1P9, Canada. erichyndman@shaw.ca.
Abstract
INTRODUCTION: While an elevated PSA significantly increases the risk of men harboring prostate cancer, many men with a persistently elevated PSA have negative prostate biopsies. More recently, multiparametric MRI (mpMRI) has had promising implications for the diagnosis of prostate cancer. We aim to investigate the diagnostic role of mpMRI in predicting the future diagnosis of prostate cancer in patients with an initial negative biopsy. METHODS: This study included all men with negative biopsies, elevated PSA and mpMRI. All patients had their age, PSA, and PSAd recorded. mpMRI lesions were classified using the PI-RADS 2 scoring system. RESULTS: mpMRI imaging was performed in 336 men with an initial negative biopsy, of whom 108, 111, 76 and 41 men underwent single, two, three and four biopsies, respectively. Of the 228 men with more than one biopsy, 115 patients were diagnosed with prostate cancer on further biopsies. Older patients and men with higher PSA, PSAd and PIRADS score had a significant risk to progress to cancer but only higher PSAd and higher PI-RADS score were significantly associated with clinically significant cancers. For clinically significant cancer; sensitivity and specificity of PI-RADS scoring was 86 and 45%, respectively, and a NPV of 87.6%. When combined with PSAd, NPV was 93%. CONCLUSION: Men with benign prostatic biopsy and both PSAd < 0.15 and low PI-RADS score may avoid second biopsy. PI-RADS scoring system has a high sensitivity to diagnose clinically significant prostate cancer and repeat biopsy should be recommended in men with benign biopsy and high score.
INTRODUCTION: While an elevated PSA significantly increases the risk of men harboring prostate cancer, many men with a persistently elevated PSA have negative prostate biopsies. More recently, multiparametric MRI (mpMRI) has had promising implications for the diagnosis of prostate cancer. We aim to investigate the diagnostic role of mpMRI in predicting the future diagnosis of prostate cancer in patients with an initial negative biopsy. METHODS: This study included all men with negative biopsies, elevated PSA and mpMRI. All patients had their age, PSA, and PSAd recorded. mpMRI lesions were classified using the PI-RADS 2 scoring system. RESULTS: mpMRI imaging was performed in 336 men with an initial negative biopsy, of whom 108, 111, 76 and 41 men underwent single, two, three and four biopsies, respectively. Of the 228 men with more than one biopsy, 115 patients were diagnosed with prostate cancer on further biopsies. Older patients and men with higher PSA, PSAd and PIRADS score had a significant risk to progress to cancer but only higher PSAd and higher PI-RADS score were significantly associated with clinically significant cancers. For clinically significant cancer; sensitivity and specificity of PI-RADS scoring was 86 and 45%, respectively, and a NPV of 87.6%. When combined with PSAd, NPV was 93%. CONCLUSION:Men with benign prostatic biopsy and both PSAd < 0.15 and low PI-RADS score may avoid second biopsy. PI-RADS scoring system has a high sensitivity to diagnose clinically significant prostate cancer and repeat biopsy should be recommended in men with benign biopsy and high score.
Entities:
Keywords:
Multiparametric MRI; Negative biopsy; PI-RADS; PSA density; Prostate cancer
Authors: Andrew B Rosenkrantz; Sadhna Verma; Peter Choyke; Steven C Eberhardt; Scott E Eggener; Krishnanath Gaitonde; Masoom A Haider; Daniel J Margolis; Leonard S Marks; Peter Pinto; Geoffrey A Sonn; Samir S Taneja Journal: J Urol Date: 2016-06-16 Impact factor: 7.450
Authors: Florian A Distler; Jan P Radtke; David Bonekamp; Claudia Kesch; Heinz-Peter Schlemmer; Kathrin Wieczorek; Marietta Kirchner; Sascha Pahernik; Markus Hohenfellner; Boris A Hadaschik Journal: J Urol Date: 2017-03-31 Impact factor: 7.450
Authors: Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Maria De Santis; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Vsevolod B Matveev; Paul C Moldovan; Roderick C N van den Bergh; Thomas Van den Broeck; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Philip Cornford Journal: Eur Urol Date: 2016-08-25 Impact factor: 20.096
Authors: Samuel Borofsky; Arvin K George; Sonia Gaur; Marcelino Bernardo; Matthew D Greer; Francesca V Mertan; Myles Taffel; Vanesa Moreno; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey Journal: Radiology Date: 2017-10-20 Impact factor: 11.105
Authors: Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton Journal: Lancet Date: 2017-01-20 Impact factor: 79.321
Authors: Michele Fascelli; Soroush Rais-Bahrami; Sandeep Sankineni; Anna M Brown; Arvin K George; Richard Ho; Thomas Frye; Amichai Kilchevsky; Raju Chelluri; Steven Abboud; M Minhaj Siddiqui; Maria J Merino; Bradford J Wood; Peter L Choyke; Peter A Pinto; Baris Turkbey Journal: Urology Date: 2015-12-08 Impact factor: 2.633
Authors: V J Gnanapragasam; K Burling; A George; S Stearn; A Warren; T Barrett; B Koo; F A Gallagher; A Doble; C Kastner; R A Parker Journal: Sci Rep Date: 2016-10-17 Impact factor: 4.379
Authors: Juan Morote; Angel Borque-Fernando; Marina Triquell; Anna Celma; Lucas Regis; Richard Mast; Inés M de Torres; María E Semidey; José M Abascal; Pol Servian; Anna Santamaría; Jacques Planas; Luis M Esteban; Enrique Trilla Journal: Cancers (Basel) Date: 2022-05-11 Impact factor: 6.575
Authors: Antonio C Westphalen; Farhad Fazel; Hao Nguyen; Miguel Cabarrus; Katryana Hanley-Knutson; Katsuto Shinohara; Peter R Carroll Journal: Int Braz J Urol Date: 2019 Jul-Aug Impact factor: 1.541